Compare FOLD & TNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOLD | TNL |
|---|---|---|
| Founded | 2002 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.0B |
| IPO Year | 2007 | N/A |
| Metric | FOLD | TNL |
|---|---|---|
| Price | $14.29 | $73.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $26.11 | ★ $73.50 |
| AVG Volume (30 Days) | ★ 7.8M | 587.2K |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 3.15% |
| EPS Growth | N/A | ★ 3.11 |
| EPS | N/A | ★ 6.07 |
| Revenue | $598,704,000.00 | ★ $3,967,000,000.00 |
| Revenue This Year | $21.49 | $4.45 |
| Revenue Next Year | $18.46 | $4.34 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | ★ 21.28 | 3.60 |
| 52 Week Low | $5.51 | $37.77 |
| 52 Week High | $14.38 | $76.21 |
| Indicator | FOLD | TNL |
|---|---|---|
| Relative Strength Index (RSI) | 79.26 | 53.17 |
| Support Level | $14.30 | $70.38 |
| Resistance Level | $14.31 | $73.33 |
| Average True Range (ATR) | 0.03 | 1.90 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 35.00 | 69.80 |
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.